The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.
March 24th 2023
Both the high-concentration and low-concentration versions of adalimumab-adaz (Hyrimoz) injection will launch in July, along with a wave of other biosimilars to Humira (reference adalimumab).
Retinal Physicians Report Reservations Around Ophthalmology Biosimilars
February 20th 2023There are 2 ranibizumab biosimilars approved in the United States, and with more ranibizumab and the first aflibercept biosimilars on the horizon, gaps in knowledge among retinal physicians should be addressed.
Read More
PBMs Announce 2023 Coverage Plans for Adalimumab Biosimilars
January 1st 2023The addition of adalimumab biosimilars to formularies can help accelerate realized savings as the blockbuster drug Humira faces competition from multiple biosimilars, including 1 approved interchangeable biosimilar.
Read More
Oncologists’ Perceptions and Utilization of US Therapeutic Oncology Biosimilars
Biosimilar use in clinical practice is determined by oncologists’ perceptions of and willingness to prescribe them. The authors investigated US oncologists’ perceptions and use of biosimilars.
Read More
US Biosimilars Substantially More Expensive Than Those in Germany, Switzerland
December 5th 2022Due to anticompetitive practices, the United States lags Germany and Switzerland in the number of biosimilars on the market, while also having substantially higher prices for both biosimilars and reference products.
Read More
Driving Biosimilar Uptake in Rheumatology, Biosimilar-to-Biosimilar Switching: ACR Abstracts
November 26th 2022Abstracts show that institutions can make internal changes to drive the use of biosimilars and that successful biosimilar-to-biosimilar switching is based on patient-related factors.
Read More
The Price Paradox of Biosimilar-Like Long-Acting Insulin
Findings suggest that Basaglar was not less expensive for patients than Lantus. Empirical evaluation of biosimilar costs prior to automatic substitution is necessary.
Read More
Rheumatologists Grow More Comfortable With Biosimilars, but Concerns Remain
November 4th 2022Ahead of the big wave of adalimumab biosimilars launching in the US market in 2023, rheumatologists report growing confidence in using biosimilars but remain concerned about their efficacy and economic benefit.
Read More
Medicare Part B Pricing Changes Aimed at Encouraging Biosimilar Use Begin
October 3rd 2022One of the first parts of the landmark Inflation Reduction Act took effect Monday; it boosts the add-on payment for qualifying biosimilars whose average sales price is not more than the price of its reference product from 6% of the reference product’s ASP to 8% for 5 years.
Read More
Multiple Pegfilgrastim Administration Options Allow for Patient-Centric Model of Care
September 20th 2022With 6 pegfilgrastim biosimilars approved, and multiple administration options, a patient-centric model of pegfilgrastim administration should be possible for patients with cancer who require prophylaxis of febrile neutropenia.
Read More
Evaluation of Biosimilar Trastuzumab MYL-1401O in HER2-Positive Breast Cancer
September 14th 2022The authors evaluate the effect and safety of biosimilar trastuzumab MYL-1401O in human epidermal growth factor receptor 2 (HER2)–positive early-stage (neoadjuvant and adjuvant therapy) and metastatic (palliative therapy) breast cancer using real-world data.
Read More
Practices Have to Grapple With the Logistics of Insurers’ Preferred Biosimilars: Dr Lalan Wilfong
September 11th 2022While commercial payers have been engaged with the shift to biosimilars, they all have their own preferred biosimilar, which makes it challenging for practices, explained Lalan Wilfong, MD, vice president of payer relations & practice transformation at The US Oncology Network.
Watch